Randomized trial to compare acceptability of magnesium sulphate administration for preeclampsia and eclampsia: Springfusor pump versus standard of care
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0286361 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Sam Ononge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Kampala, Uganda. Hauptthemen laut MEDLINE: Magnesium Sulfate, Pre-Eclampsia, Eclampsia, Standard of Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: FIC NIH HHS, NIH Office of the Director.
Abstract (Originalsprache)
Introduction
In low-resource settings, magnesium sulphate (MgSO 4) for preeclampsia is administered majorly through an injection into the gluteal muscles 4-hourly for 24 hours. The repeated injections are very painful and may lead to infection, abscess formation, and reduced compliance.
Objective
To determine the acceptability of Springfusor® pump for the administration of Magnesium Sulphate in preeclampsia and eclampsia.
Design
Randomized Open Label Clinical Trial.
Methods
The study was conducted at Kawempe National Referral Hospital. Eligible women had a systolic blood pressure of ≥ 1 40mmHg and or diastolic blood pressure >90mmHg, proteinuria ≥+1, and the physician’s decision to start on MgSO 4 . Four-hundred-ninety-six participants were randomized to a Springfusor® pump group (n = 248) or control (standard of care) (n = 248) administration of MgSO 4 . Intervention group had a loading dose (4gm of 50% MgSO 4 intravenously over 20 minutes) and maintenance therapy (1gm of 50% MgSO 4 intravenously per hour for 24 hours) administered using the Springfusor®. The standard of care (SOC) group received a loading dose of 4gm of 20% MgSO 4 IV over 15–20 minutes, followed by 10gm of 50% MgSO 4 intramuscular (5gm in each buttock) and a maintenance dose of 5gm of 50% MgSO 4 was administered IM every 4 hours for 24 hours. Both arms received the rest of the care for preeclampsia/eclampsia as per the hospital guidelines. Acceptability of the method of administration was assessed using a Likert scale (1–5; 1 and 2: acceptable and 3–5: unacceptable). Pain at the site of MgSO 4 administration was assessed using a Visual Analogue Scale 1–7, (1 minimal pain and 7 worst pain). Comparisons were assessed with the Chi-square test, Mann Whitney-Wilcoxon test, and Students’ t-test.
Results
Intervention arm; was more acceptable than the standard of care arm, (95.3% vs70.3%; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Kampala, Uganda.
- University of Washington, Seattle, Washington, United States of America.
- Gynuity Health Projects, New York, NY, United States of America.
ORCID-Profile: Sam Ononge
Förderung
- FIC NIH HHS
- NIH Office of the Director
Zitieren
APA
Ononge, S., Nakimuli, A., Byamugisha, J., Adroma, M., Kiondo, P., Easterling, T., & Bracken, H. (2024). Randomized trial to compare acceptability of magnesium sulphate administration for preeclampsia and eclampsia: Springfusor pump versus standard of care. PLOS ONE. https://doi.org/10.1371/journal.pone.0286361
Vancouver
Ononge S, Nakimuli A, Byamugisha J, Adroma M, Kiondo P, Easterling T, et al. Randomized trial to compare acceptability of magnesium sulphate administration for preeclampsia and eclampsia: Springfusor pump versus standard of care. PLOS ONE. 2024. doi:10.1371/journal.pone.0286361
BibTeX
@article{Ononge2024,
author = {Ononge, Sam and Nakimuli, Annettee and Byamugisha, Josaphat and Adroma, Moses and Kiondo, Paul and Easterling, Thomas and Bracken, Hillary},
title = {Randomized trial to compare acceptability of magnesium sulphate administration for preeclampsia and eclampsia: Springfusor pump versus standard of care},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0286361}
}
EUVIMED